This bill strengthens U.S. pharmaceutical supply chain security by requiring drug manufacturers to disclose detailed information about their ingredient sources. Specifically, pharmaceutical companies must annually report the names and locations of all suppliers of active and inactive ingredients, along with the percentage of each ingredient sourced from each supplier. The bill directs the Food and Drug Administration to publish this aggregate information on a public website while protecting proprietary details, and to share the data with the Department of Defense to assess reliance on foreign drug manufacturers. Additionally, the legislation updates trade rules to treat active pharmaceutical ingredients as domestically produced only when wholly manufactured in the United States, and requires federal drug inspectors to consider whether establishments have been inspected by foreign adversaries, focus on essential medicines with limited global suppliers, and assess whether they operate in countries with histories of exporting illicit drugs. The bill provides a 180-day deadline for updating federal acquisition regulations to align with these new sourcing rules.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.